NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 15 10:08AM ET
1.81
Dollar change
-0.02
Percentage change
-1.09
%
Index- P/E- EPS (ttm)-0.74 Insider Own23.85% Shs Outstand47.11M Perf Week-4.23%
Market Cap85.27M Forward P/E- EPS next Y-1.03 Insider Trans0.00% Shs Float35.87M Perf Month-7.65%
Enterprise Value18.57M PEG- EPS next Q- Inst Own2.22% Short Float0.22% Perf Quarter18.30%
Income-33.38M P/S852.69 EPS this Y-40.68% Inst Trans-42.98% Short Ratio1.64 Perf Half Y-6.46%
Sales0.10M P/B1.69 EPS next Y-24.10% ROA-32.56% Short Interest0.08M Perf YTD-9.05%
Book/sh1.07 P/C1.00 EPS next 5Y-22.33% ROE-55.14% 52W High3.58 -49.45% Perf Year-33.21%
Cash/sh1.81 P/FCF- EPS past 3/5Y25.96% -14.47% ROIC-65.35% 52W Low1.33 36.60% Perf 3Y-9.05%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-78.35% -26.47% Gross Margin-798.76% Volatility7.15% 6.26% Perf 5Y-
Dividend TTM- EV/Sales185.69 EPS Y/Y TTM-69.40% Oper. Margin-34881.07% ATR (14)0.13 Perf 10Y-
Dividend Ex-Date- Quick Ratio2.30 Sales Y/Y TTM-99.43% Profit Margin-32428.84% RSI (14)44.79 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio2.30 EPS Q/Q- SMA20-5.02% Beta0.74 Target Price3.50
Payout- Debt/Eq0.37 Sales Q/Q- SMA50-1.63% Rel Volume113.68 Prev Close1.83
Employees138 LT Debt/Eq0.01 EarningsMar 24 BMO SMA200-9.15% Avg Volume47.18K Price1.81
IPOFeb 09, 2021 Option/ShortNo / Yes EPS/Sales Surpr.12.12% - Trades Volume764,655 Change-1.09%
Date Action Analyst Rating Change Price Target Change
Jan-31-25Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-25-21Initiated China Renaissance Buy $40.57
Mar-08-21Initiated Morgan Stanley Overweight $34
Mar-08-21Initiated Jefferies Buy $33
Mar-08-21Initiated Goldman Buy $29
Today 07:00AM
Jul-08-25 07:00AM
Jul-01-25 07:00AM
Jun-03-25 09:40AM
May-27-25 07:30AM
05:05PM Loading…
May-22-25 05:05PM
Apr-28-25 08:00AM
Apr-23-25 10:05AM
Apr-07-25 08:00AM
Mar-24-25 08:00AM
Mar-13-25 08:00AM
Mar-06-25 08:00AM
Feb-27-25 08:00AM
Jan-27-25 07:00AM
Jan-21-25 05:00PM
08:00AM Loading…
Jan-14-25 08:00AM
Jan-08-25 09:40AM
Dec-06-24 09:40AM
Nov-20-24 09:40AM
Nov-07-24 10:01AM
Oct-09-24 06:00AM
Sep-16-24 03:01AM
Sep-11-24 09:40AM
Aug-29-24 07:00AM
Aug-26-24 09:40AM
Jul-25-24 04:05PM
Jul-12-24 07:00AM
May-22-24 04:45PM
Mar-29-24 09:00AM
Mar-07-24 04:01PM
08:00AM Loading…
Feb-27-24 08:00AM
Feb-09-24 06:00AM
Jan-17-24 07:00AM
Jan-16-24 05:01PM
Jan-04-24 05:00AM
Nov-03-23 12:00PM
Oct-30-23 09:40AM
Oct-13-23 09:40AM
Oct-12-23 08:00AM
Sep-27-23 09:40AM
Sep-07-23 10:45PM
09:40AM
Aug-31-23 07:32AM
May-25-23 09:40AM
May-04-23 09:00AM
Apr-28-23 07:00AM
Apr-18-23 09:17AM
Mar-31-23 09:40AM
06:34AM
Mar-28-23 04:30PM
Mar-14-23 06:00PM
Mar-05-23 07:39PM
Jan-09-23 07:00AM
Jan-05-23 04:01PM
Dec-16-22 06:30AM
Nov-21-22 04:05PM
Nov-10-22 09:05AM
Oct-11-22 04:03PM
Sep-10-22 04:13AM
Aug-30-22 05:25PM
Jun-29-22 04:05PM
May-26-22 09:30PM
May-12-22 07:00AM
May-02-22 06:06AM
Apr-08-22 01:09PM
Apr-03-22 02:34PM
Mar-31-22 08:30AM
Mar-17-22 10:42AM
Mar-16-22 10:00AM
07:00AM
Mar-08-22 09:21PM
Mar-02-22 08:22AM
06:00AM
Feb-08-22 07:00AM
Feb-02-22 04:05PM
Jan-27-22 07:00AM
Jan-19-22 07:00AM
Jan-13-22 04:00AM
Dec-22-21 04:05PM
Dec-13-21 10:23AM
Dec-06-21 01:49PM
06:30AM
Nov-30-21 04:01PM
Nov-29-21 04:05PM
Nov-22-21 05:05PM
Nov-09-21 04:05PM
Nov-04-21 09:24AM
Oct-27-21 08:52AM
Oct-21-21 08:00AM
Sep-17-21 12:22PM
Sep-02-21 07:45AM
Aug-26-21 07:45AM
Aug-19-21 07:37AM
07:00AM
Aug-12-21 07:45AM
Jul-22-21 07:45AM
Jul-12-21 10:15PM
Jul-09-21 10:47AM
Jul-07-21 07:45AM
Jun-16-21 04:49PM
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.